The MHRA has published an update to the Good Pharmacovigilance Practice section of their website. The update concerns the publication and distribution of updated Summaries of product Characteristics (SPCs) and Patient Information Leaflets (PILs) following safety-related changes. The MHRA recommends specific timeframes for completing activities relating to updated SPCs and PILs, following findings by the GPvP Inspectorate.
It is important for Marketing Authorisation Holders to note the expectations of the MHRA relating to timeframes for publication and distribution of these documents, to ensure timely risk communication to internal and external customers.
More information on the guidance published by the MHRA can be found by following the link below:
The MHRA are no longer sending out Anonymised Single Patient Reports (ASPRs)/ Individual Case Safety Reports (ICSRs) from literature to Marketing Authorisation Holders (MAHs). This came about after a review by the BROMI Vigilance Workstream and should increase efficiency for both the MHRA and MAH Pharmacovigilance systems. The MHRA state that the number of ASPRs sent out to companies could be reduced by 33-50%. This will be of particular interest to generic companies that hold numerous Marketing Authorisations in the UK.
The MHRA have published information about this which can be found by following the link below. It is important to continue reporting serious cases from literature in line with the MHRA’s instructions & Volume 9a to ensure continued compliance. If you have any questions about ASPRs and how to manage them, please contact us and we will be happy to help you.
The European Commission is seeking the views of stakeholders on the implementing measures for the performance of the new activities that were introduced by the amended Pharmacovigilance legislation.
The public consultation on these measures is open to all – do not miss the opportunity to have your say and gain further insight into the new Pharmacovigilance legislation that comes into force in July 2012.
The concept paper and more information on how to provide your feedback can be found by following the link below. The deadline for comments is 7th November 2011.
The GPvP Risk Based Inspection Compliance Reports are due for submission to the MHRA by 4th November 2011 – please mark this date in your diary! Completion of the report is not mandatory but the MHRA recommend that Marketing Authorisation Holders do complete one. If you do not submit a completed report the MHRA will assign your company a high risk rating, increasing your chances of a Pharmacovigilance Inspection. More information can be found at
We are very proud to announce that Purple Vigilance Limited, a Pharmacovigilance Consultancy, was established in September 2011. This website is under construction and will be completed soon, please check back regularly for updates. Please see the About Us and PV Services page for more information. Please feel free to contact us to discuss your current or future requirements.